CN108354923A - Application of the dihydromyricetin in preparing anti-influenza virus medicament - Google Patents
Application of the dihydromyricetin in preparing anti-influenza virus medicament Download PDFInfo
- Publication number
- CN108354923A CN108354923A CN201711139676.9A CN201711139676A CN108354923A CN 108354923 A CN108354923 A CN 108354923A CN 201711139676 A CN201711139676 A CN 201711139676A CN 108354923 A CN108354923 A CN 108354923A
- Authority
- CN
- China
- Prior art keywords
- dihydromyricetin
- virus
- influenza
- cell
- pb2cap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The application that the invention discloses dihydromyricetins in preparing anti-influenza virus medicament.The influenza virus is influenza A virus, preferably H1N1, H3N2, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 or H10N8.Mechanism of action in the dihydromyricetin anti-influenza A virus be by and the combination of PB2cap albumen inhibit ribonucleoprotein complexes vRNP activity, prepare the drug for preventing and treating influenza.Wherein, the histidine (His432) that dihydromyricetin is 432 with the protein bound sites influenza virus PB2cap, 357 histidines (His357), 404 phenylalanines (Phe404), 323 phenylalanines (Phe323), 361 glutamic acid (Glu361), 376 lysine (Lys376), 363 phenylalanines (Phe363), 429 asparagines (Asn429).
Description
Technical field
The application that the present invention relates to dihydromyricetins in anti-influenza A virus medicament, belongs to pharmaceutical technology field.
Background technology
Influenza seriously threatens the health of the mankind as a kind of viral infectious and hinders the development of social economy.A type stream
Influenza Virus causes up to more than one hundred million person-times of the cases of infection in the whole world every year, has the characteristics that high pathogenicity rate and high lethality.In history
It is very popular caused by having broken out four influenza viruses altogether, is all caused by animal derived influenza virus spans host's barrier.
1997, avianInfluenza virus H5N occurred for Hong Kong, and 1 leads to human breathing tract disease and dead epidemic situation and spreads to more
A country, lethality are more up to 50%, exacerbate fear of the people for HPAI (High Pathogenic AI) virus.In March, 2013, in
State first appears people and infects H7N9 cases, and rapid progress is pneumonia, respiratory failure, Respiratory Distress Syndrome(RDS), dead, case fatality rate
About 40%.By the end of in June, 2017, Global Raport infects H7N9 totally 1538, and 732, and two are just reported in inland of China
Example H7N9 the infected's virus has morphed.The prevention of the prevention of influenza, especially drug has been extremely urgent.
So far, the anti-influenza virus medicament clinically used is mainly：M2 inhibitors of ion channels (amantadine,
Rimantadine)；NA inhibitor (Oseltamivir, zanamivir, Peramivir)；RNA polymerase inhibitor (the Li Bawei of wide spectrum
Woods, Favipiravir), but persister is gradually generated during antiviral drugs use, also consider what these drugs generated
Neurotoxicity so that the urgent searching of people novel anti-influenza A virus medicament and strategy.
Influenza A virus is made of eight full-length genomes of HA, NA, M, NS, PA, PB1, PB2, NP, wherein PA, PB1,
PB2 constitutes RNA polymerase, mediates the transcription and replication of virus.Since the surface antigen of influenza A virus is easily mutated,
Center of gravity is transferred on highly conserved RNA polymerase by researcher, is designed and is developed corresponding inhibitor, become anti influenza
One new direction of drug research..Influenza virus RNA polymerase complex is made of tri- subunits of PB1, PB2 and PA, wherein
The multi-functional basic protein of PB2 subunits is made of 759 amino acid, and there are one special nucleophilic sequence areas for tool, and effect is in disease
When virus gene group is transcribed, participates in identification and recruit primer of 5 ' the end cap minor structures of host mRNA as transcription, the combination of PB2cap
Site is located at 318~483 amino acids full regions.The combination of 5 ' the end cap-like structures of PB2 and host cell mRNAs is transcription
The initial step of viral mRNA, if we can find it is a kind of can be with small point of the closer combination of PB2 cap-like structure binding sites
Son, this micromolecular can competitively occupy PB2 cap-like structure binding sites, then just influenza virus can be blocked in body from source
Interior duplication.
In recent years, have many study found that many flavones, tannic acid, alkaloid and terpenoid have in various degree
Anti influenza acts on, therefore natural monomeric compound is the important sources of Tamiflu.Our early-stage studies find yellow
The small molecule traditional Chinese medicine monomer of ketone Polyphenols can effective anti-influenza A virus, such as scutelloside, Quercetin, cyanidenon.
Dihydromyricetin is a kind of vine tea flavonoid class compound, is widely present in Vitaceae ampelopsis, research finds two
Hydrogen myricetin has antitumor, anti-oxidant, blood pressure lowering, inhibits a variety of pharmacological activity such as internal thrombosis.
Invention content
It is an object of the invention to a kind of novel resisiting influenza virus inhibitor is found from natural products.The dihydro
Myricetin, the activity with significant anti-influenza A virus, can be as new anti-influenza virus medicament and lead compound
It is developed, is with a wide range of applications.Specifically, present invention discover that dihydromyricetin can inhibit influenza A virus,
Be combineding with each other for PB2cap and host cell cap-like structure can be specifically destroyed, the duplication of virus is influenced, can be used as novel anti-
Flu-A lead compound is researched and developed.
The structure of the dihydromyricetin is shown in formula I in the inventive solutions,
The dihydromyricetin can inhibit the duplication of Influenza virus H1N1 and H3N2 in host cell.
The dihydromyricetin can target the PB2cap albumen of influenza virus, to inhibit itself and host cell cap-like structure
Combination and vRNP activity, can be used for being prepared into the drug of anti-influenza A virus.
The histidine (His432) that the dihydromyricetin is 432 with the protein bound sites influenza virus PB2cap,
357 histidines (His357), 404 phenylalanines (Phe404), 323 phenylalanines (Phe323), 361
Glutamic acid (Glu361), 376 lysine (Lys376), 363 phenylalanines (Phe363), 429 asparagines
(Asn429), it can inhibit vRNP activity to replicate with influenza virus, to play resisiting influenza virus effect.
The dihydromyricetin can be made into a variety of pharmaceutically acceptable dosage forms, such as tablet, granule, pulvis, capsule, mouth
Liquid, injection etc. are taken, the treatment of influenza is used for.
The drug of above-mentioned various dosage forms can be prepared according to the conventional method of pharmaceutical field.
In conclusion compared with the prior art, the present invention has the following advantages and effect：
1. dihydromyricetin can inhibit the infection of Influenza virus H1N1 and H3N2 to cell, disease-resistant with wide spectrum
Cytotoxic activity.
2. dihydromyricetin is smaller to the toxicity of cell, to the CC of mdck cell and A549 cells50Be 505.1 respectively ±
12.8、328.5±4.315μM.IC of the dihydromyricetin to Influenza virus H1N1 and H3N250It is divided into 15.18 ± 0.92,
23.33 ± 4.83 μM, safety index is 33.3 and 21.7 respectively, can be used as safely and effectively anti-influenza virus medicament and is opened
Hair.
3. dihydromyricetin acts on the cap calmodulin binding domain CaM of influenza virus PB2 albumen, can Reverse transcriptase PB2 albumen with
Host mRNA 5 ' holds the combination of cap-like structure, and the transcription of influenza virus is prevented to replicate.
Description of the drawings
Fig. 1 dihydromyricetin cytotoxicities detect.A. toxicity of the dihydromyricetin to mdck cell；B. dihydromyricetin pair
The toxicity of A549 cells.
The activity of Fig. 2 dihydromyricetin anti-influenza A virus.A. dihydromyricetin is to different influenza A virus strains
Inhibitory activity；B. dihydromyricetin inhibits cytopathy caused by influenza A virus；C. dihydromyricetin inhibits Flu-A
Plaque test caused by virus.
Fig. 3 dihydromyricetins inhibit duplication of the influenza virus in cell.A. dihydromyricetin inhibits influenza virus to exist
The expression of NP albumen in mdck cell；B. dihydromyricetin inhibits the expression of influenza virus NP albumen in mdck cell；C. two
Hydrogen myricetin reduces the expression of virus NP mRNA in mdck cell.
Fig. 4 dihydromyricetin infected by influenza enters the influence of target cell.
Fig. 5 dihydromyricetins act on the stage after influenza infection.
Fig. 6 dihydromyricetins inhibit the proreduplication of influenza virus.
Fig. 7 dihydromyricetins can be combined with PB2cap albumen concentration dependents.A.FP is experiments have shown that dihydromyricetin can
It is combined with PB2cap albumen concentration dependents；C.SPR is experiments have shown that dihydromyricetin has combination with PB2cap albumen.
The active influence of Fig. 8 dihydromyricetin infected by influenza vRNP.
The molecular docking of Fig. 9 dihydromyricetins and PB2cap albumen.
Specific implementation mode
In order to better understand the content of the present invention, with reference to experiment and result to dihydromyricetin in anti-influenza A
Application in virus further illustrates.
Materials Cell used in the present invention and virus
Dog renal epithelial cell (mdck cell), human lung cancer epithelial cell (A549) and 293T cells are containing 10% tire ox blood
Clearly, 100U/L penicillin, the DMEM of streptomysin or 1640 culture mediums are cultivated.Influenza A virus A/PR/8/34 (H1N1),
H1N1FM-1 and A/Aichi/2/68 (H3N2) selects chicken embryo passage amplification in 8-9 days, -80 DEG C of preservations.Plasmid A/Thailand/
Kan353/2004-HA, A/Thailand/Kan353/2004-NA and pNL4-3R-E-Luc are used for the preparation of H5N1 pseudovirus.
Wherein pNL4-3R-E-Luc is to carry out frameshift mutation in pNL4-3 it is made not express Env albumen and Vpr albumen, and be inserted into fluorescence
One recombinant plasmid of plain enzyme reporter gene.PHW2K-PB1, pHW2K-PB2, pHW2K-PA, pHW2K-NP and pPolI-Flu with
And hRluc-TK is tested for mini-replicon, wherein pHW2K-PB1, pHW2K-PB2, pHW2K-PA, pHW2K-NP are thin
RNP compounds are formed after dysuria with lower abdominal colic dye.Wherein all with live virus correlation test is carried out in 2 grades or 3 grades facilities of bio-safety.
The cytotoxicity of 1 dihydromyricetin of embodiment detects
Dihydromyricetin uses mtt assay to the detection of cytotoxicity, so that it is determined that the activity of drug.Specific method is such as
Under:
MDCK or A549 cells press 1 × 104/ hole is inoculated in 96 orifice plates, at 37 DEG C, 5%CO2Constant temperature cell incubator
Middle culture is to single layer, with being added in 96 orifice plates after DMEM or 1640 gradient dilution dihydromyricetins without serum, per hole 200
μ l continue to cultivate 48h.Culture supernatant is abandoned, 1640 or the DMEM culture mediums of 100 μ L MTT containing 0.5mg/ml of addition per hole, 37 DEG C
It is incubated 4h.Using absorbance at multi-function microplate reader (Genios Pro, Tecan, US) detection 570nm.With the survival rate of cell
As dihydromyricetin to the index of the toxicity of MDCK or A549 cells.
Cell survival rate (%)=E/N × 100
E is the absorbance of medicine group, and N is the absorbance of cell controls group.
Test result：Dihydromyricetin cytotoxicity is small, and biological safety is high
The results are shown in Figure 1, and the toxicity of two kinds of cells of dihydromyricetin pair is smaller.It is selected in the experimental study of the present invention
Drug concentration is in safety non-toxic concentration range within 100 μM.
The Activity determination of the external anti-influenza A virus of 2 dihydromyricetin of embodiment
The influenza A virus of a variety of hypotypes involved in antiviral study in vitro of the present invention, including H1N1 and H3N2, specifically
Method is as follows：
Mdck cell presses 2 × 104/ hole is inoculated in 96 orifice plates, at 37 DEG C, 5%CO2Constant temperature cell incubator in cultivate
To single layer.Use 100TCID50PR8 infection cells after 37 DEG C are incubated 1h, abandon virus liquid per 100 μ l of hole, DMEM is added and (contains 1 μ
G/ml TPCK) dihydromyricetin of gradient dilution continues to cultivate 48h per 200 μ l of hole.In conjunction with mtt assay and plaque assay, reflection
The antiviral activity of dihydromyricetin measures the protective effect of cell by dihydromyricetin, including observation dihydromyricetin
Inhibit cell virus phenomenon (CPE) caused by virus and detect the survival rate of cell, and further calculates medium effective concentration
IC50。
Test result：Dihydromyricetin can inhibit the infection of influenza virus
Test result：Fig. 2A shows that dihydromyricetin has apparent inhibiting effect to Influenza virus H1N1 and H3N2,
To the medium effective concentration IC of both strains of H1N1 and H3N250It is divided into 15.18 ± 0.92,23.33 ± 4.83 μM, selectivity is pacified
Total index number distinguishes 33.27 and 21.7 (tables 1).Shown in Fig. 2 B, 100TCID50Virus liquid can cause after infection cell 48h obviously
Cytopathy, dihydromyricetin can generate protective effect to cell.Fig. 2 C show that dihydromyricetin is capable of concentration dependent
Inhibit the formation of plaque.
1 dihydromyricetin anti-influenza A virus activity of table
The Inhibition test that 3 dihydromyricetin of embodiment replicates influenza A virus
In order to assess dihydromyricetin infected by influenza duplication inhibiting effect, the present invention using indirect immunofluorescence,
Tri- kinds of methods of Q-PCR and Western blotting, detect dihydromyricetin from the expression of gene and albumen respectively
Influence to virus replication.The specific method is as follows：
Indirect immunofluorescence：Mdck cell presses 5 × 104/ hole is inoculated in 48 orifice plates, at 37 DEG C, 5%CO2Constant temperature it is thin
It is cultivated to single layer in born of the same parents' incubator.Use 100TCID50PR8 infection cells after 37 DEG C are incubated 1h, abandon virus liquid, add per hole 1ml
The dihydromyricetin for entering DMEM (containing 1 μ g/ml TPCK) gradient dilution continues culture for 24 hours per 500 μ l of hole.Hereafter, with 4%
Paraformaldehyde is fixed after 20min to NP albumen and nuclear targeting, and the expression that NP albumen is taken in multiple visuals field is randomly selected；
Q-PCR and Western blot：Mdck cell presses 4 × 105/ hole is inoculated in 6 orifice plates, at 37 DEG C, 5%CO2's
It is cultivated to single layer in constant temperature cell incubator.With the PR8 infection cells of 100TCID50 after 37 DEG C are incubated 1h, disease is abandoned per hole 1ml
Venom, the dihydromyricetin that DMEM (containing 1 μ g/ml TPCK) gradient dilution is added after continuing culture for 24 hours, use 1ml per hole 1ml
The abundant lytic cells of TRIzol simultaneously extract total serum IgE, and sample is used for Q-PCR；Or contain protease and inhibitors of phosphatases with 70-80 μ l
RIPA lysates lytic cell and extract total protein on ice, sample is for Western blot experiments.
Test result:Dihydromyricetin can inhibit duplication of the influenza virus in cell.
Fig. 3 A and Fig. 3 B are the expressions for detecting virus N P in mdck cell.From the results, it was seen that dihydromyricetin
Element can significantly decrease the expression of viral NP protein, and have concentration dependent.Fig. 3 C are examined using the method for Q-PCR
The expression of virus N P mRNA is surveyed, compared with virus control group, dihydromyricetin can inhibit the expression of NP gene mRNAs
Amount, and with the increase of concentration, inhibiting effect is more apparent.The result and indirect immunofluorescence and Western blotting
As a result consistent.Each experiment is independently repeated 3 times, and is analyzed with the statistical analysis method of One-Way ANOVA.It is each real
It tests and is independently repeated 3 times, analyzed with the statistical analysis method of One-Way ANOVA.
4 dihydromyricetin infected by influenza of embodiment enters the influence of target cell.
The present invention enters the influence of target cell using H5N1 pseudovirus systems detection dihydromyricetin infected by influenza.H5N1
Pseudovirus system refers to the A/Thailand/Kan353/2004-HA and A/Thailand/ with influenza virus envelopes albumen
The core protein pNL4-3R-E-Luc plasmid co-transfection 293T cells of Kan353/2004-NA plasmids and HIV, the vacation being assembled into
Virus contains envelope protein hemagglutinin HA, and the absorption of mediate retroviral is invaded, and virus-free the of self-replication capacity, only has single-wheel
Infectivity, biological safety is high, can be completed in 2 grades of laboratories of bio-safety.The specific method is as follows：
Mdck cell presses 1 × 104/ hole is inoculated in 96 orifice plates, at 37 DEG C, 5%CO2In cell incubator culture to 80~
90%.The pseudovirus of the dihydromyricetin of 50 μ l doubling dilutions and 50 μ l is incubated 30min at 37 DEG C.It, will be viral after 30min
It is added to jointly in 96 orifice plates with the mixture of dihydromyricetin, at 37 DEG C, 5%CO2Continue to cultivate in cell incubator.48h
Afterwards, culture supernatant is abandoned, is operated according to Luciferase Assay Reagent box specification, the infection ability of virus is detected, 50 μ are added per hole
The cell pyrolysis liquid of l is then drawn the cell pyrolysis liquid in 40 μ l, 96 orifice plates, is added to as 20min is vibrated on oscillator
In the flat luciferase detection plate in 96 holes, the luciferase substrate of 40 μ l is then added simultaneously；Luciferase is surveyed with microplate reader
Values of chemiluminescence.According to the size of values of chemiluminescence, the activity that dihydromyricetin inhibits viruses adsorption to enter is judged.
Compound inhibiting rate (%)=[1- (E-N)/(P-N)] × 100
Wherein, E represents the values of chemiluminescence of experimental group, and N represents the values of chemiluminescence of negative control group, and P represents positive right
According to the values of chemiluminescence of group.Half-inhibition concentration (the IC of compound50) as compound anti-influenza virus activity index.Sun
Property comparison medicine be CL-385319.
Test result:Dihydromyricetin does not influence influenza virus and enters target cell.
In order to study whether dihydromyricetin influences the absorption invasion of virus.From dihydromyricetin shown in Fig. 4 experimental results
It cannot inhibit H5N1 pseudovirus target cell infections, show that dihydromyricetin does not act on the stage that influenza virus enters target cell.
The influence of 4 dihydromyricetin infected by influenza life cycle of embodiment.
In order to determine that dihydromyricetin interferes which of the influenza virus life cycle stage, we use different administrations
It is administered before mode, including infection, administration, whole administration are studied after infection.Method is as follows：Mdck cell is inoculated with 100TCID50
Influenza A virus after, using three kinds of different dosing methods, before infecting administration (pre-treatment) refer to virus and dihydro
Myricetin adds cell infection 1h after being incubated 30min, then replaces the fresh maintaining liquid without dihydromyricetin；After infection
Dihydromyricetin is added after referring to virus infected cell in administration (post infection)；Whole process administration (entire treatment)
Refer to after virus, dihydromyricetin and cell are incubated 1h altogether and is substituted for the fresh maintaining liquid containing dihydromyricetin.Virus infection is thin
After born of the same parents 48 hours, the antivirus action of dihydromyricetin is detected with the method for above-mentioned 1-3.
Test result:Dihydromyricetin acts on the stage after influenza infection.
Before Fig. 5 shows that dihydromyricetin infects the metainfective inhibiting rate of virus higher than virus, dihydromyricetin is shown
Mainly act on the virus metainfective stage.
The influence that 6 dihydromyricetin of embodiment replicates virus transcription
In order to determine which of the dihydromyricetin viral interference life cycle stage, the present invention is by changing dihydromyricetin
The plain mode of action and time are studied.The specific method is as follows：
During viral single-wheel replicates, according to time interval (0-1,1-3,3-5,5-8, the 8- after virus infected cell
10h), the maintaining liquid containing dihydromyricetin is added in cell, the maintaining liquid without compound is added then in disease in other times
After poison infection 10h, sample is collected, using the expression of Western blot detection virus protein Ns P.Cell is added in dihydromyricetin
In time it is as shown in Figure 6.
Test result:Dihydromyricetin acts on duplication early period of virus
The different time intervals administration of (0-10h) during the single-wheel of virus replicates, dihydromyricetin can be apparent in 1-3h
The expression that must inhibit influenza NP protein shows that dihydromyricetin acts on the duplication early period of virus and plays antiviral work
With.
7 dihydromyricetin of embodiment can competitively combine PB2cap
We using fluorescent energy polarization transfer (FP) and surface plasma resonance (SPR) determine dihydromyricetin and
The combination of PB2cap albumen.
FP is tested：By PB2cap albumen and FITC-m7The mixed liquor of GTP is added to 96 hole blackboards, in every 50 μ l of hole, room temperature
Lower incubation 30min；Above-mentioned solution is added after dihydromyricetin is carried out 2 times of doubling dilutions with buffer solution, per 50 μ l of hole, at room temperature
It is incubated 1h；Finally fluorescence polarization value is measured with multi-function microplate reader.
SPR is tested：Dihydromyricetin to be measured is fixed on by photo-crosslinking instrument on 3D photo-crosslinking chips, room temperature point sample；
The mutual of dihydromyricetin and PB2cap albumen is detected using PlexArray HT biomolecular interaction analysis instrument at room temperature
Effect：PB2cap albumen is first diluted to 250nM, 500nM, 1000nM, the albumen of various concentration with 0.05%PBS-T (pH 7.0)
Sample is as analyte with 2 μ Ls-1Speed pass through analyzer；Binding time is 300s, Dissociation time 300s, is selected sweet
Propylhomoserin hydrochloric acid (pH 2.0) lives again to chip as liquid of living again, and flow velocity is 3 μ Ls-1；Using PlexeraDE softwares to reality
It tests result to be analyzed and handled, be mapped with 8.0 softwares of origin.
Test result:FP test results show that dihydromyricetin can competitively combine PB2cap, and are in concentration dependant
Property (Fig. 7 A).SPR experiment further demonstrate that dihydromyricetin can with PB2cap protein bindings, binding constant KD values be 8.28 ×
10-6Mol/L (Fig. 7 B).
8 dihydromyricetin of embodiment is on the active influences of vRNP
This experiment uses Reverse Genetics, and the plasmid of tetra- kinds of structures of PB1, PB2, PA, NP is total in 293T cells
Transfection forms vRNP compounds, and whether verification dihydromyricetin is by inhibiting the activity of the activity suppression RNP of PB2cap.Specific side
Method is as follows：
Mini-replicon is tested:293T cells are with 2 × 105A/hole is inoculated in 24 orifice plates, waits for that cell is grown to 90% left side
The right side carries out the transfection of plasmid according to 2000 transfection reagent specifications of Lipofectamine.25 μ l are contained into 50ng pHW2K-
The blank DMEM culture mediums of PB1, pHW2K-PB2, pHW2K-PA, pHW2K-NP and pPolI-Flu and 10ng hRluc-TK add
Enter in the blank DMEM culture mediums for containing 1 μ g Lipofectamine 2000 to 25 μ l, the transfection composite of formation is added to
In cells and supernatant, continues to cultivate 5h, replace the fresh DMEM culture solutions containing compound and 10%FBS；Continue to cultivate
After for 24 hours, culture supernatant is abandoned, is detected according to dual luciferase reporter gene detection kit specification, specific operation is such as
Under：The passive lysate of 100 μ l is added per hole, the cell pyrolysis liquid of 20 μ l is taken to be detected to 96 hole white fluorescent element enzymes after oscillator
In plate；The luciferase substrate of 50 μ l is added per hole, detects the fluorescent value of Fluc with multi-function microplate reader immediately；
The prepared termination reaction solutions of 50 μ l are added per hole, detect the fluorescent value of Renilla luciferase with multi-function microplate reader immediately；RNA
The ratio of the fluorescent value of the active Fluc of polymerase and the fluorescent value of Renilla luciferase indicates, according to than
Value calculates inhibiting rate of the compound to RNA polymerase：
Inhibiting rate (%)=(RRNP-Fsample)/(FRNP-Fblank) × 100%
Test result:Dihydromyricetin influences the activity of influenza virus vRNP
293T cells are transfected by tetra- kinds of albumen of PB1, PB2, PA and NP to virus, present invention discover that dihydromyricetin
It can inhibit the activity (Fig. 8) of viral vRNP, and there is concentration dependent.Illustrate that dihydromyricetin is logical in conjunction with Fig. 7 results
The combination with PB2cap albumen is crossed, the activity of vRNP is inhibited, to influence the duplication of virus.
The combination of dihydromyricetin and PB2cap albumen is analyzed in 9 molecular docking of embodiment
The present invention downloads PB2cap albumen from Protein Data Bank, and (PDB is numbered：4CB4, resolution ratio：)。
The combination of dihydromyricetin and PB2cap albumen is simulated using AutoDock softwares.Before carrying out molecular docking, Dock is first used
Prep modules add hydrogen atom, respectively albumen and the ligand molecular addition field of forces AMBER ff4SB and AM1-BCC charges.Using
DMS tools in Chimera are with radiusProbe generate albumen molecular surface, using sphgen modules generation enclose
Around the spherical set (Spheres) of active site, Grid files are generated using Grid modules, this document is for being quickly based on
The energy scoring of Grid is evaluated.Then use DOCK6 programs to carry out flexible docking, generate 10000 different conformations be orientated with
And electrostatic and Van der Waals interaction in acquisition compound and binding pocket between residue, and Grid marking is thus calculated.
By clustering, (RMSD threshold values are), obtain best conformation of giving a mark.Finally, it is interacted by protein ligand
Line analysis tool Protein-Ligand Interaction Profier analysis results, and picture is generated using PyMOL
(Fig. 9).
Test result:Dihydromyricetin by and PB2cap structures in Conservative amino acid residue combination, influence
The activity of vRNP inhibits the transcription and replication of virus.
In conjunction with above result of study, dihydromyricetin acts on duplication early period of virus, by making with PB2cap albumen
With the duplication for inhibiting influenza virus.Then, the present invention is using AutoDock softwares simulation dihydromyricetin and PB2cap albumen
In conjunction with.The results are shown in Figure 9, and the binding site of dihydromyricetin molecule and PB2cap albumen is 432 histidines respectively
(His432), 357 histidines (His357), 404 phenylalanines (Phe404), 323 phenylalanines
(Phe323), 361 glutamic acid (Glu361), 376 lysine (Lys376) shape 363 phenylalanine (Phe363)
And 429 asparagines (Asn429), via analysis, in conjunction with amino acid residue in be high conservative mostly, such as table 2
It is shown.
The conservative Analysis of table 2 dihydromyricetin and PB2cap binding sites
In summary described as a result, dihydromyricetin has the function of anti-influenza A virus, and dihydromyricetin resists
Virus function mechanism is and the combination of PB2cap albumen is to inhibit the activity of RNA polymerase, to influence answering for influenza virus
System.Therefore, dihydromyricetin has toxicity low, active high, inexpensive easily as new anti-influenza virus medicament and lead compound
It obtains, the feature that mechanism is clear, there is good application prospect.
Claims (6)
1. application of the compound in preparing anti-influenza virus medicament shown in a kind of Formulas I
2. application according to claim 1, it is characterised in that：The influenza virus is influenza A virus.
3. application according to claim 2, it is characterised in that：The influenza A virus be H1N1, H3N2, H5N1,
H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 or H10N8.
4. application of the compound shown in Formulas I in preparing the drug for inhibiting influenza A virus to replicate early period.
5. compound shown in Formulas I is preparing the application for inhibiting influenza A virus in the drug that target cell is replicated.
6. compound shown in Formulas I prepare can with PB2cap protein bindings inhibit and host cell cap-like structure combination and
The active drug of vRNP.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711139676.9A CN108354923A (en) | 2017-11-16 | 2017-11-16 | Application of the dihydromyricetin in preparing anti-influenza virus medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711139676.9A CN108354923A (en) | 2017-11-16 | 2017-11-16 | Application of the dihydromyricetin in preparing anti-influenza virus medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108354923A true CN108354923A (en) | 2018-08-03 |
Family
ID=63009934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711139676.9A Pending CN108354923A (en) | 2017-11-16 | 2017-11-16 | Application of the dihydromyricetin in preparing anti-influenza virus medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108354923A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109512814A (en) * | 2018-10-27 | 2019-03-26 | 李定文 | A kind of purposes of anti-fog haze drug and its anti-haze mask and dihydromyricetin in prevention and treatment haze and treatment seasonal influenza |
| CN111728965A (en) * | 2020-06-05 | 2020-10-02 | 华中科技大学同济医学院附属同济医院 | Application of compound in preparation of antiviral drug |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772398A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Application of dihydromyricetin in preparation of drug preventing and treating influenza |
-
2017
- 2017-11-16 CN CN201711139676.9A patent/CN108354923A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772398A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Application of dihydromyricetin in preparation of drug preventing and treating influenza |
Non-Patent Citations (1)
| Title |
|---|
| BILL ROSCHEK JR 等: "Elderberry flavonoids bind to and prevent H1N1 infection in vitro", 《PHYTOCHEMISTRY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109512814A (en) * | 2018-10-27 | 2019-03-26 | 李定文 | A kind of purposes of anti-fog haze drug and its anti-haze mask and dihydromyricetin in prevention and treatment haze and treatment seasonal influenza |
| CN111728965A (en) * | 2020-06-05 | 2020-10-02 | 华中科技大学同济医学院附属同济医院 | Application of compound in preparation of antiviral drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Serkedjieva et al. | In vitro anti-influenza virus activity of a plant preparation from Geranium sanguineum L. | |
| Jones et al. | Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells | |
| Choi et al. | Antiviral activity of ethanol extract of Geranii Herba and its components against influenza viruses via neuraminidase inhibition | |
| Petit et al. | Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2 | |
| Milewska et al. | Novel polymeric inhibitors of HCoV-NL63 | |
| Shin et al. | Broad‐spectrum antiviral effect of Agrimonia pilosa extract on influenza viruses | |
| CN106138040B (en) | Dendrobine is preparing the application in anti-influenza virus medicament | |
| Shao et al. | Spring viraemia of carp virus enters grass carp ovary cells via clathrin-mediated endocytosis and macropinocytosis | |
| CN107898778A (en) | Application of the myricetin in anti-influenza virus medicament is prepared | |
| CN108354923A (en) | Application of the dihydromyricetin in preparing anti-influenza virus medicament | |
| Huang et al. | A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance | |
| CN104151403A (en) | Polypeptide or derivative thereof and application of polypeptide or derivative in influenza virus infection | |
| CN110870864B (en) | Application of carbinoxamine maleate in preparation of anti-influenza virus medicine | |
| Yu et al. | In vitro antiviral efficacy of moroxydine hydrochloride and ribavirin against grass carp reovirus and giant salamander iridovirus | |
| CN103720687B (en) | The application of dicoumarol in the medicine preparing treatment or flu-prevention viral infection | |
| CN103705497B (en) | Application of liothyronine in preparation of medicine for treatment or prevention of influenza virus infection | |
| CN103705506B (en) | Application of enilconazole in preparing drug for treating or preventing influenza virus infections | |
| CN107898783B (en) | Application of 1, 3-dihydroxy-6-benzo [ C ] chromene in preparing anti-influenza virus medicine | |
| Garaev et al. | Antiviral properties of synthetic histidine derivatives containing membranotropic volumetrical carbocycles in their molecule against SARS-CoV-2 virus in vitro | |
| CN108721264B (en) | Application of isoxsuprine in preparing medicine for treating or preventing influenza virus infection | |
| CN110151767B (en) | Application of GNF-7 in preparation of medicine for treating influenza virus infection | |
| CN115813929B (en) | Application of S63845 in preparation of anti-influenza virus infection medicines | |
| CN103720684B (en) | The application of bentrl hydrothloride in preparation treatment or flu-prevention virus infective medicament | |
| CN106491583B (en) | Application of the cirsimaritin in preparation antiviral drugs | |
| CN107286044A (en) | It is a kind of to suppress the compound that influenza virus PB2 albumen is combined with RNA caps |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180803 |
|
| RJ01 | Rejection of invention patent application after publication |